No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.0x · 10Y median 2.5x · 65th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:41.244Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:21:41.244Z. Latest historical point 2026-10-05.
The latest delayed quote for Elutia Inc (ELUT) stock was $0.82 as of Oct 5, 2026, 4:00 PM EDT, up 5.51% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -6.6% · 3-year avg -14.0%/yr · 5-year avg -34.0%/yr
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular.
Biotechnology · Gaithersburg, MD
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.15
Revenue Est.
$1.00M
Last Quarter Results
EPS
$-0.17
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ELUT | $36.32M | $0.82 | +5.51% | -6.61% | -33.96% | N/A | N/A |
| 2BEAT | $36.31M | $0.65 | +50.53% | -66.28% | N/A | N/A | vs ELUT |
| 3BCTX | $36.37M | $4.18 | +3.47% | -67.87% | -67.32% | -52.81% | vs ELUT |
| 4DCGO | $36.05M | $0.36 | -1.22% | -71.09% | -48.40% | N/A | vs ELUT |
| 5ELTX | $36.61M | $1.92 | +0.00% | -82.46% | N/A | N/A | vs ELUT |
| 6ARAY | $35.89M | $0.30 | +7.37% | -82.00% | -39.94% | -25.77% | vs ELUT |
$2.43M
vs Estimate
$2.90M
Consensus Rating
Based on 1 analyst
Average Price Target
$5.00
+508.6% upside
Low
$5.00
Current
$0.82
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Dec 2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| FY 2027 | $-0.54 | $-0.54 | $-0.54 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.00M | $1.00M | $1.00M | 1 |
| Quarter ending Dec 2026 | $1.00M | $1.00M | $1.00M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $7.50M | $7.50M | $7.50M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $4.30M |
| $4.30M |
| $4.30M |
| 1 |
